Can I read OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands on EtoBox?

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands by Monica R Gadelha; Harpal Singh Randeva; Murray B Gordon; Mirjana Doknic; Emese Mezosi; Miklos Toth; Cesar Luiz Boguszewski; Christine T Ferrara-Cook; Alessandra Casagrande; Alan Krasner is a Medicine article available to read on EtoBox.

What is OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands about?

## Abstract **Disclosure: M.R. Gadelha:** Advisory Board Member; Self; Crinetics Pharmaceuticals, Ipsen, Novo Nordisk, and Recordati Rare Diseases. Research Investigator; Self; Crinetics Pharmaceuticals and Recordati Rare Diseases. Speaker; Self; Crinetics Pharmaceuticals, Ipsen, Novo Nordisk, and Recordati Rare Diseases. **H.S. Randeva:** None. **M.B. Gordon:** Consulting Fee; Self; Crinetics Pharmaceuticals, HRA Pharma, Novo Nordisk, and Recordati Rare Diseases. Grant Recipient; Self; Ascendis, Camurus, Chiasma, Corcept, Crinetics, Ipsen, Novartis, Novo Nordisk, Opko, Pfizer, and Strongbridge. **M. Doknic:** Advisory Board Member; Self; Pfizer in CEE region. Research Investigator; Self; Crinetics Pharmaceuticals, Pfizer, Camurus, Ascendis, Opko, Ipsen, and Teva. Speaker; Self; Pfizer, Novartis, Novo Nordisk, Sandoz, and Merck. **E. Mezosi:** Research Investigator; Self; Crinetics Pharmaceuticals. **M. Toth:** Consulting Fee; Self; Ipsen, Novartis, Pfizer, and Recordati Rare Diseases. Research Investigator; Self; Crinetics Pharmaceuticals. **C.L. Boguszewski:** Consulting Fee; Self; Novo Nordisk. Research Investigator; Self; Crinetics Pharmaceuticals and Recordati Rare Diseases. S

Who reads OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands?

Author

Monica R Gadelha; Harpal Singh Randeva; Murray B Gordon; Mirjana Doknic; Emese Mezosi; Miklos Toth; Cesar Luiz Boguszewski; Christine T Ferrara-Cook; Alessandra Casagrande; Alan Krasner

Publisher

The Endocrine Society

Published

2023

Field

Medicine (Health Sciences)